Pfizer (NYSE:PFE) Stock

PFIZER INC

Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Pfizer Inc

Innovator U.S. Equity Power Buffer ETF - February

PFEIFFER VACUUM TECH ORD by Pfeiffer Vacuum Technology AG

Pfeiffer Vacuum Technology AG

Several exemptions exist among President Donald Trump&#8216;s <a href="https://www.benzinga.com/markets/25/04/44621408/market-access-has-a-price-trump-unveils-list-of-tariffs-countries-targeted" target="_blank" rel="noopener">broad tariffs</a>, which were announced on Wednesday. 
The biopharma industry has historically been shielded from tariffs, including during Trump&#8217;s first term. Given its significant manufacturing presence in Europe, investors had feared global tariffs could disrupt the sector.
Morningstar <a href="https://www.morningstar.com/stocks/biopharma-industry-exempt-global-10-tariff-we-still-see-margin-tax-rate-risks" target="_blank" rel="noopener">reports</a> that with the U.S. importing approximately $200 billion in pharmaceuticals in 2024, a 10% tariff could have cost the industry $20 billion, with some of the largest firms facing annual tariffs of up to $1 billion.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44642463/french-president-macron-suggests-suspension-of-eu-investments-in-us-amid-tariff-turmoil" rel="noreferrer noopener">French President Macron Suggests Suspension Of EU Investments In US Amid Tariff Turmoil, Vows &#8216;More Powerful&#8217; Response</a>
Goldman Sachs expects continued volatility in the biotechnology sector (XBI and S&amp;P 500 are down about 14% and 7% year-to-date, respectively), driven by broader economic <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44631606/trumps-tariff-exemptions-include-semiconductors-pharmaceuticals-oil-and-more" rel="noreferrer noopener">uncertainty and unclear healthcare policy</a>.
Analyst Salveen Richter has analyzed geographic exposure and tax rates for individual companies and sees Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) and Alnylam Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) in the strongest position, followed by Gilead Sciences Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Amgen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) and Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>).
Regeneron Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) raises some concerns due to its significant presence in Ireland. If tariffs are applied, they would likely increase the cost of goods sold since companies often import ingredients or finished products into the U.S.
Analyst Richter adds that <a target="_blank" href="https://www.benzinga.com/quote/AMGN" rel="noreferrer noopener">Amgen</a>, <a target="_blank" href="https://www.benzinga.com/quote/ALNY" rel="noreferrer noopener">Alnylam</a>, <a target="_blank" href="https://www.benzinga.com/quote/BIIB" rel="noreferrer noopener">Biogen</a>, and <a target="_blank" href="https://www.benzinga.com/quote/REGN" rel="noreferrer noopener">Regeneron</a> are the least exposed to Medicaid risk.
Goldman Sachs said Friday that it&#8217;s been hard to measure the exact impact of potential tariffs on U.S. biopharma due to limited public data on where drugs are made.
Their analysis shows limited manufacturing exposure to Canada, Mexico and China. Pharmaceuticals from Canada and Mexico are also likely exempt under the USMCA trade deal. However, some companies do rely heavily on manufacturing in the EU.
If tariffs are placed on drugs made outside the U.S. and kept in place, they could raise manufacturing costs. Companies often import ingredients or finished products before selling them in the U.S. Some manufacturers are reportedly speeding up shipments from Europe out of concern that tariffs may apply to <a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noopener">those products,</a><a href="https://www.benzinga.com/general/biotech/25/03/44440233/pharmaceutical-firms-say-uk-investment-is-unlikely-unless-payment-levy-is-adressed" target="_blank" rel="noreferrer noopener"> too</a>.
Goldman Sachs is also watching for exceptions or phased rollouts, pointing to a similar eight-year grace period in the Biosecure Act.
Still, the analyst writes that biopharma companies are generally resilient due to their high profit margins and globally spread operations.
Companies that produce small-molecule drugs might handle a U.S. manufacturing shift better than those making biologics since small molecules require less complex production.
Senator Ron Wyden has raised concerns about Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) and Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>) using offshore setups to reduce U.S. taxes.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/25/04/44648087/karman-strikes-90m-deal-for-mti-enhancing-position-in-next-gen-defense-technologies" target="_blank" rel="noreferrer noopener">Karman Strikes $90M Deal For MTI, Enhancing Position In Next-Gen Defense Technologies</a></li>
</ul>
Photo: Shutterstock

Biotech

Government

Large Cap

News

Health Care

General

ALNY

AMGN

BIIB

GILD

REGN

VRTX

Vertex, Alnylam Best Positioned As Biopharma Braces For Tariff Impact, Goldman Sachs Flags Regeneron, Biogen Risks

For many investors, dividend-focused <a href="https://in.benzinga.com/25/03/44565770/30-year-old-with-65k-in-stocks-sparks-debate-focusing-mostly-on-etfs-but-now-betting-on-bonds-small-caps-and-international-plays">stocks</a> and funds provide a way to generate passive income, whether to supplement retirement, cover day-to-day <a href="https://in.benzinga.com/personal-finance/25/02/43768530/should-married-couples-split-expenses-dave-ramsey-says-no-youre-married-not-roommates">expenses</a>, or even finance small luxuries like annual vacations.
While some aim for significant <a href="https://in.benzinga.com/personal-finance/25/03/44518501/20-year-old-university-student-wants-help-with-buying-dividend-stocks-whats-the-best-way-to-start-reddit-weights-in">dividend</a> payouts to replace their salary, others are happy with modest but constant returns that offer a little extra financial freedom.
Don't Miss:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>
This is the case of a Reddit user who is exploring this approach. With $30,000 to invest, he's seeking long-term dividend stocks that can grow over the next 20 years until retirement. While he already holds dividend-paying stocks like Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Walt Disney&nbsp; (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>), he wants to expand his portfolio for stability and future income, even if it's just enough to cover yearly vacations.
&#8220;I currently have some stocks that give out dividends (Apple, Disney) but I&#8217;m looking for others. Long-term stability, that my wife and I can use the dividends as another form of income say in 20 years. Even if it&#8217;s just enough to pay for a yearly vacation here or there. Any thoughts on good companies to choose from?&#8221; he asked.
Let&#8217;s break down the Redditors&#8217; advice received in the comment section.
Trending: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
<h2 class="wp-block-heading">Where to Invest $30,000 to Generate Enough Income to Cover Yearly Vacations? Reddit Answers</h2>
Put the Money in an ETF
Several commenters recommended Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>) as a core holding because of its dividend yield, historical growth, and the low-risk, diversified exposure it offers investors.
&#8220;Go all in SCHD. Low risk, nice 3.5% starting yield and it will just keep growing,&#8221; a commenter said.
Reinforcing the idea that SCHD fits the poster&#8217;s long-term stability and dividend payout need, this Redditor also suggested he goes with SCHD: &#8220;Since you want some growth and decent payout, SCHD is a great option. 3.5% dividends and 11% growth over the last 10 years each year.&#8221;
&#8220;I would stick with S&amp;P 500 ETFs being young. Put it in a self-direct investment retirement account to avoid taxes,&#8221; a comment reads.
See Also: Have $200K saved?<a href="https://www.benzinga.com/money/have-200k-saved-heres-how-to-turn-it-into-lasting-wealth"> Here's how to turn it into lasting wealth</a>
Consider High-Yield Dividend Stocks and Trusts
Several commenters suggested higher-yield assets that would generate higher payouts for the investor in the long run.
&#8220;If you want higher yield stocks check: [Verizon Communications (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vz#NYSE">VZ</a>)], [AT&amp;T (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/t#NYSE">T</a>)], [Realty Income Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/o#NYSE">O</a>)], [Altria Group (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mo#NYSE">MO</a>)], [British American Tobacco (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bti#NYSE">BTI</a>)],&#8221; a Redditor recommended.
A commenter mentioned United Parcel Service (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) as a great pick since the company seems to start focusing on higher profit margin areas.
&#8220;UPS pays a solid dividend and the share price has been beaten down a lot on the news that they are reducing Amazon deliveries to focus on higher profit margin areas,&#8221; he said.
Suggesting a very detailed portfolio allocation, this Redditor mentioned several ETFs and individual stocks that he considers would help the poster reach his dividend and growth goals.
&#8220;[Vanguard S&amp;P 500 ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/voo#NYSE">VOO</a>)] $5,000, 1.25% dividends. Do [dividend reinvestment plan] SCHD $5,000, 3.5% dividends. Do [dividend reinvestment plan], [JPMorgan Equity Premium Income ETF (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jepi#NYSE">JEPI</a>)], [JPMorgan Nasdaq Equity Premium Income ETF (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jepq#NASDAQ">JEPQ</a>)​] ($5,000), 8% combined dividends. Do [dividend reinvestment plan] [Old Republic International Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ori#NYSE">ORI</a>)] $2,000, 3% dividends. Do [dividend reinvestment plan] [Waste Management (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/wm#NYSE">WM</a>)] and [Automatic Data Processing (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adp#NASDAQ">ADP</a>)] ($3,000), 2% average dividend. Do [dividend reinvestment plan] [Pfizer (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pfe#NYSE">PFE</a>)] and [Johnson &amp; Johnson (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jnj#NYSE">JNJ</a>)] $2,000, 4.75% average dividend. Do [dividend reinvestment plan] [JPMorgan Chase &amp; Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/jpm#NYSE">JPM</a>)] and [UnitedHealth Group Incorporated (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/unh#NYSE">UNH</a>)] $2,000, 2% average dividends. Do [dividend reinvestment plan] AAPL and [Microsoft (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/msft#NASDAQ">MSFT</a>)] $2,000. [The Coca-Cola Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ko#NYSE">KO</a>)] and MO $2,000, 5% average dividends. Do [dividend reinvestment plan] JPM or [American Express (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/axp#NYSE">AXP</a>)] $2,000. JPM has good potential growth,&#8221; the suggestion says.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
</ul>

Personal Finance

AAPL

JEPI

JEPQ

MSFT

SCHD

Man With $30K To Deploy Wants Dividends For Life – 'Even If It's Just Enough To Pay For A Yearly Vacation Here Or There,' Reddit Reacts

The U.K&#8217;s National Institute for Health and Care Excellence (NICE) on Wednesday recommended Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Adcetris (brentuximab vedotin) for adult patients with <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">advanced Hodgkin lymphoma</a>.
The recommendation covers brentuximab vedotin in combination with other therapies for routine National Health Service (NHS) use.
Around 800 people annually with <a target="_blank" href="https://www.nice.org.uk/news/articles/first-ever-nhs-treatment-approved-for-advanced-hodgkin-lymphoma" rel="noreferrer noopener">previously</a> untreated stage 3 or 4 CD30-positive Hodgkin lymphoma could benefit from this treatment, which combines brentuximab vedotin with doxorubicin, dacarbazine, and vinblastine.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44504682/pfizer-shares-are-down-today-whats-going-on" rel="noreferrer noopener">Pfizer Shares Are Down Today: What&#8217;s Going On?</a>
NICE says this marks the first recommendation specifically for previously untreated late-stage classical Hodgkin lymphoma and follows an improved confidential discount to the NHS on the treatment&#8217;s list price offered by Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>).
Clinical evidence from the ECHELON-1 trial showed that brentuximab combination therapy significantly delays disease progression and prolongs survival compared to standard chemotherapy regimens.
The trial demonstrated impressive overall survival rates. Hodgkin lymphoma is a type of cancer that affects cells in the lymphatic system. Advanced (stage 3 and 4) CD30-positive Hodgkin lymphoma most commonly affects younger adults aged 20 to 24 years and older <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44578528/european-commission-approves-pfizers-rsv-vaccine-abrysvo-to-help-protect-adults-aged-18-59-against" rel="noreferrer noopener">adults aged 75 to 79 years</a>.
NICE recommendation means the treatment will be available immediately through the Cancer Drugs Fund, with interim funding provided until routine commissioning begins.
On Tuesday, the European Commission issued a decision amending the marketing authorization for Pfizer&#8217;s Abrysvo, the company&#8217;s bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, to extend the indication to include prevention of lower respiratory tract disease (LRTD) caused by RSV in individuals 18 through 59 years of age.
The approval is based on results from the pivotal phase 3&nbsp;MONeT&nbsp;trial.
Price Action: PFE stock is up 0.35% at $24.63 at the last check on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44592073/tariffs-could-shake-building-industry-homebuilders-plumbing-flooring-face-rising-costs" target="_blank" rel="noreferrer noopener">Tariffs Could Shake Building Industry: Homebuilders, Plumbing, Flooring Face Rising Costs</a></li>
</ul>
Photo via Shutterstock

UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients

<ul>
<li>ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49</li>
</ul>

Pfizer's ABRYSVO RSV Vaccine Gains EU Approval For Adults Aged 18-59, Offering Broader Protection Against Lower Respiratory Tract Disease

If you&#8217;ve been paying attention to the stock market recently, you must have come across a rather unexpected turn of events—value stocks are taking center stage from their flashy growth rivals. Over the course of three months, the Russell 1000 Value Index has <a href="https://www.benzinga.com/general/market-summary/25/03/44555763/value-stocks-are-crushing-growth-superstars-in-2025-is-more-to-come">beaten the Russell 1000 Growth Index </a>by a healthy 11%. That&#8217;s a far cry from this time last year, when tech and AI plays were driving the market upwards.
Also Read: <a href="https://www.benzinga.com/etfs/new-etfs/25/03/44569468/growth-or-value-allsprings-new-etfs-offer-both">Growth Or Value? Allspring&#8217;s New ETFs Offer Both</a>
With tariffs, geopolitical tensions, and recession jitters swirling, investors are flocking to the relative safety of value stocks. But is it a permanent pivot, or a temporary sidetrack? Although no one knows for sure what the market will do, history suggests that value stocks have a way of surviving rough patches.
For those looking to ride the wave, these <a href="https://www.benzinga.com/etfs">four value-based ETFs</a> are worth considering:
iShares Russell 1000 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWD#NYSE">IWD</a>)
The first choice for most investors seeking to follow the Russell 1000 Value Index, IWD offers broad exposure to large-cap value stocks from a wide range of sectors, such as financials, healthcare, and consumer staples. Some of its holdings include stocks of JP Morgan Chase &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>), Exxon Mobil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>) and Procter &amp; Gamble Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PG#NYSE">PG</a>). With its size and liquidity, this ETF is a convenient means of achieving diversified exposure to the value sector. It carries an expense ratio of 0.19%.
Vanguard Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VTV#NYSE">VTV</a>)
An affordable fund with a bottom-of-the-barrel expense ratio of 0.04%, VTV tracks the CRSP US Large Cap Value Index. Blue-chip stalwarts such as JPMorgan Chase, and Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) are overweights in this fund, which is a good bet for stability and long-term growth.
SPDR S&amp;P 500 Value ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPYV#NYSE">SPYV</a>)
If you desire exposure to value stocks as part of the larger S&amp;P 500, SPYV may be considered. This ETF targets S&amp;P 500 stocks that reflect strong value features in terms of low price-to-earnings and price-to-book ratios. With the valuation differential between value and growth stocks as high as it is now, this ETF is poised to profit from a possible market correction. The portfolio is similar to that of IWD and VTV, and the expense ratio is 0.04%.
Schwab U.S. Dividend Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCHD#NYSE">SCHD</a>)
Dividend stocks tend to overlap with value stocks, and SCHD is a good representative of this case. Concentrating on high-grade dividend-paying businesses, this ETF not only gets investors exposed to value stocks but also provides a steady income under market uncertainty. Its portfolio carries blue-chip brands such as Coca-Cola (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KO#NYSE">KO</a>), PepsiCo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEP#NASDAQ">PEP</a>), and Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>). This ETF comes with an expense ratio of 0.06%.
Also Read: <a href="https://www.benzinga.com/25/03/44570070/tariffs-inflation-and-tumbling-markets-these-5-etfs-thrived-amid-the-chaos-last-week">Tariffs, Inflation And Tumbling Markets: These 5 ETFs Thrived Amid Last Week&#8217;s Chaos</a>
Why Value Could Stay On Top
Last quarter&#8217;s value outperformance is more than just jitters in the market. It&#8217;s because, as BlackRock&#8217;s Global CIO of Fundamental Equities Tony DeSpirito <a href="https://www.blackrock.com/us/individual/insights/value-stocks-underweight-and-unaware?utm_source=chatgpt.com">says</a>, growth stocks now comprise almost 40% of the S&amp;P 500—more than double their long-term average of 24%. With the valuations pulled forward, investors might begin shifting into value stocks for diversification. In addition, sectors like utilities, health care, and materials—staples in value indexes—are less tariff-vulnerable and potentially even positively affected by changes in trade policy.
While growth stocks may recover over time, the current market environment has favored value stocks. For those interested in exploring this trend, these four ETFs offer examples of funds that focus on value investing.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/03/44570028/westwoods-new-bfre-etf-prioritizes-democracy-over-autocracy">Westwood&#8217;s New BFRE ETF Prioritizes Democracy Over Autocracy</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

ETFs

SPYV

Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend

Vaxcyte Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCVX#NASDAQ">PCVX</a>) on Monday released topline results from its Phase 2 dose-finding study evaluating the safety, tolerability and immunogenicity of VAX-24, a 24-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease (IPD), compared to Pfizer Inc&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Prevnar 20&nbsp;(PCV20) <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">in healthy infants</a>.
The company has selected the VAX-24 Mid-dose as the basis for advancing an optimized dose formulation to a potential Phase 3 program.
Pending the VAX-31 infant Phase 2 study topline data results anticipated in mid-2026, it plans to initiate an infant Phase 3 study with <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/g44558031/vaxcyte-announces-positive-topline-results-from-vax-24-infant-phase-2-dose-finding-study" rel="noreferrer noopener">either VAX-24 or VAX-31</a>.
In this Phase 2 study, VAX-24 was well-tolerated and demonstrated a safety profile similar to PCV20 across all doses studied.
Frequently reported local and systemic reactions were generally mild to moderate, resolving within several days of vaccination, with no meaningful differences observed across the cohorts.
No serious adverse events were considered to be related to the study vaccines.
Post-dose 3, the VAX-24 Mid dose met target precedent Phase 2 non-inferiority (NI) criteria on relative seroconversion rates, particularly for the highest circulating serotypes2&nbsp;contained in VAX-24 and for 20 of 24 serotypes overall.
The Mid dose also met the target Phase 2 IgG Geometric Mean Ratio (GMR) point estimate of &gt;0.63&nbsp;on all currently circulating serotypes contained in VAX-24 and for 22 of 24 serotypes overall.
Post-dose 3, VAX-24 generated robust OPA responses, which are correlated with effectiveness against IPD across all serotypes and doses.
The four serotypes unique to VAX-24 elicited immune responses and met all target criteria across all endpoints at all doses evaluated post-dose 3 (primary immunization series).
Dose-dependent immune responses were consistently demonstrated at 1.1mcg, 2.2mcg, and 4.4mcg doses. Little to no carrier suppression was observed.
Full post-dose 4 booster data is expected by the end of 2025.
An interim assessment of the IgG results was performed with currently available study samples and demonstrated:
<ul>
<li>The Mid dose met the company&#8217;s historical target Phase 2 IgG GMR point estimate of &gt;0.6 for the highest circulating serotypes contained in VAX-24 and for 19 of 24 serotypes overall.</li>
<li>VAX-24 elicited memory responses across all doses for all serotypes.</li>
</ul>
Price Action: PCVX stock is down 29.5% at $48.99 during the premarket session at the last check Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44544677/regulatory-uncertainty-meets-power-surge-jp-morgans-take-on-talen-constellation-and-vistra-stocks" target="_blank" rel="noreferrer noopener">JP Morgan&#8217;s Stock Picks In The Power Sector Amid Regulatory Uncertainty</a></li>
</ul>
Photo: Shutterstock

Movers

Trading Ideas

PCVX

Vaxcyte Plans To Drop Developing One Pneumococcal Conjugate Vaccine

MRNA

President Trump Says Will Be Announcing Pharma Tariffs Soon

Pfizer's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) short percent of float has risen 4.17% since its last report. The company recently reported that it has 99.17 million shares sold short, which is 1.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.22 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Pfizer Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743192028_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Pfizer has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Pfizer's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Pfizer's peer group average for short interest as a percentage of float is 4.18%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

What Does the Market Think About Pfizer?

CureVac N.V.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVAC#NASDAQ">CVAC</a>) on Thursday said the European Patent Office (EPO) confirmed the validity of CureVac&#8217;s European patent EP 3 708 668 B1 subject to amendments to specify <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">the scope of protection</a>.
The opposition division largely dismissed the opposition originally filed by BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) in April 2023, challenging the patent&#8217;s validity and maintaining the patent in amended form.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/02/43598644/deadly-bird-flu-strain-detected-in-nevada-man-4-stocks-to-watch" rel="noreferrer noopener">Deadly Bird Flu Strain Detected In Nevada Man: 4 Stocks To Watch&nbsp;</a>
The <a href="https://www.benzinga.com/pressreleases/25/03/ac44524866/curevac-receives-positive-validity-decision-from-european-patent-office-in-litigation-against-bio" target="_blank" rel="noreferrer noopener">ruling</a> represents a major milestone in the ongoing patent dispute between CureVac and BioNTech in Germany. The legal spat involves six intellectual property rights.
Following Thursday&#8217;s ruling, the Regional Court Düsseldorf will decide whether the patent in its amended form has been infringed.
An infringement hearing is scheduled for July 1, 2025. A positive infringement decision would trigger proceedings to assess damages in the same court.
EP 3 708 668 B1 describes a foundational invention of CureVac, called split poly-A tail technology. It enhances medical efficacy by improving the expression of the protein encoded on an mRNA construct.
Last April, Canadian biotech company Acuitas Therapeutics and CureVac settled Acuitas&#8217; lawsuit over credit for inventions tied to COVID-19 vaccines.
Acuitas&nbsp;told&nbsp;the court that CureVac omitted its scientists from patent applications for lipid nanoparticle technology used in messenger RNA-based vaccines after collaborating to develop the <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38468361/covid-19-patent-dispute-sorted-acuitas-therapeutics-and-curevac-reach-settlement-in-patent-battle" rel="noreferrer noopener">technology during the COVID-19 pandemic</a>.
This move&nbsp;would&nbsp;allow Acuitas to license them without CureVac&#8217;s consent.&nbsp;
In December 2023, a German court invalidated a patent central to&nbsp;CureVac&#8217;s lawsuit against&nbsp;BioNTech&nbsp;related to seeking fair compensation for infringement of a portfolio of CureVac&#8217;s intellectual property rights utilized in Comirnaty, BioNTech, and&nbsp;Pfizer Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/12/36305189/why-is-covid-19-vaccine-player-curevac-stock-plummeting-today" rel="noreferrer noopener">mRNA COVID-19 vaccine</a>.
Price Action: CVAC stock is up 17.5% at $3.29 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/contracts/25/03/44532830/rocket-lab-joins-us-space-forces-5-6-billion-launch-program-stock-soars" target="_blank" rel="noreferrer noopener">Rocket Lab Joins US Space Force&#8217;s $5.6 Billion Launch Program; Stock Soars</a></li>
</ul>
Image: Shutterstock

Legal

BNTX

CVAC

European Patent Office Rules Vaccine Developer CureVac's Amended Patent Valid, Stock Jumps

The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S&#8217;&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) Tivdak (tisotumab vedotin) for advanced or recurrent cervical cancer that has progressed on or <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">after cancer chemotherapy</a>.
Tivdak is the first and only antibody-drug conjugate (ADC) to be approved for <a target="_blank" href="https://www.benzinga.com/pressreleases/25/03/b44511989/tivdak-tisotumab-vedotin-approved-by-japan-ministry-of-health-labour-and-welfare-for-the-treatment" rel="noreferrer noopener">cervical cancer in Japan</a>.
The approval is based on data from the Phase 3 innovaTV 301 clinical trial that evaluated the efficacy and safety of TIVDAK compared to chemotherapy in patients with advanced or recurrent cervical cancer who were previously treated with chemotherapy.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/06/39532534/abbviegenmabs-epkinly-fda-approval-is-a-positive-step-analyst-says-additional-expan" rel="noreferrer noopener">AbbVie/Genmab&#8217;s Epkinly FDA Approval Is A Positive Step, Analyst Says Additional Expansion Opportunities Underway</a>
The trial included 502 patients, 101 of which were Japanese.
The trial met its primary endpoint of overall survival (OS), demonstrating a 30% reduction in risk of death compared to chemotherapy.
Median OS was 11.5 months among patients treated with Tivdak compared to 9.5 months for patients who received chemotherapy. Secondary endpoints of progression-free survival (PFS) and confirmed objective response rate (ORR) were also met.
Tisotumab vedotin is co-developed and co-commercialized globally by Genmab and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) under an agreement in which the companies share costs and profits.
With respect to the commercialization of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer, Genmab leads commercialization in Japan and all other regions globally, outside the United States and China. In these regions, Pfizer partners with Genmab and Zai Lab, respectively, on commercialization.
Price Action: GMAB stock is up 3.06% at $20.22 at the last check Thursday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/offerings/25/03/44511664/why-is-teslas-chinese-rival-nio-stock-diving-today" target="_blank" rel="noreferrer noopener">Why Is Tesla&#8217;s Chinese Rival NIO Stock Diving Today?</a></li>
</ul>

Asia

GMAB

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) shares are trading lower on Wednesday after a <a href="https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247">Wall Street Journal </a>report revealed U.S. prosecutors are investigating a claim about the timing of Pfizer's COVID-19 vaccine announcement.
What To Know: The claim, brought forward by British pharmaceutical company GSK, alleges Pfizer may have delayed announcing the success of its vaccine trials in 2020 until after the U.S. presidential election.
According to sources, the investigation stems from a GSK scientist, who used to work at Pfizer, allegedly telling his GSK colleagues that Pfizer delayed the vaccine results, a claim President Donald Trump repeated for years without evidence. The scientist disputes that he did this, stating Pfizer worked as quickly as possible to secure FDA approval.
Prosecutors have already interviewed at least two individuals in connection with the claim, including a GSK executive who documented the conversation. A third person is expected to be interviewed soon, though Pfizer executives have not yet been questioned. Pfizer maintains that its vaccine development was driven purely by science and regulatory oversight, dismissing any allegations of impropriety. The company has not received formal inquiries from prosecutors.
Trump, who has long criticized the timing of Pfizer's announcement, has personally questioned Pfizer CEO Albert Bourla about the matter. Bourla has denied any deliberate delay. Internal reports indicate that Pfizer aimed for an October 2020 completion but faced the complexities of clinical trials and regulatory approval.
The investigation adds another layer to the ongoing rivalry between Pfizer and GSK, which have battled over COVID-19 treatments and RSV vaccine patents in recent years. 
PFE Price Action: Pfizer shares closed Wednesday down 1.33% at $25.21, according to <a href="http://www.benzinga.com/pro/register/?utm_source=BZprocontent072624&amp;t=be2bearmibe3na1">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="531" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26163632/Screenshot-2025-03-26-at-16.36.10-1024x531.png" alt="" class="wp-image-843565" style="width:493px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26163632/Screenshot-2025-03-26-at-16.36.10-1024x531.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26163632/Screenshot-2025-03-26-at-16.36.10-300x155.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26163632/Screenshot-2025-03-26-at-16.36.10-768x398.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/03/26163632/Screenshot-2025-03-26-at-16.36.10.png 1507w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44502165/lululemon-athletica-q4-earnings-preview-analyst-sees-buying-opportunity-with-positive-risk-reward">Lululemon Athletica Q4 Earnings Preview: Analyst Sees &#8216;Buying Opportunity&#8217; With Positive Risk/Reward</a></li>
</ul>
Photo: Shutterstock.

Pfizer Shares Are Down Today: What's Going On?

WIIM

Pfizer shares are trading lower following a Wall Street Journal report suggesting US prosecutors are probing a tip about the timing of the company's COVID-19 vaccine, which allegedly came via GSK.

<a href="https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247" title="https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247">https://www.wsj.com/health/pharma/pfizer-covid-vaccine-2020-election-probe-2f3ec247</a>

'U.S. Prosecutors Probe Tip About Timing Of Pfizer Vaccine; Claim Came To The U.S. Attorney's Office In Manhattan Via Pfizer Rival GSK' - WSJ

The U.S. Food and Drug Administration has approved Exelixis Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXEL#NASDAQ">EXEL</a>) Cabometyx (cabozantinib) for two indications in adult and pediatric patients with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic and extra-<a href="https://www.benzinga.com/general/health-care" target="_blank" rel="noreferrer noopener">pancreatic neuroendocrine tumors (NET)</a>.
NETs are heterogeneous tumors arising from the digestive tract&#8217;s neuroendocrine cells and other organs, <a href="https://www.benzinga.com/pressreleases/25/03/b44493504/exelixis-announces-u-s-fda-approval-of-cabometyx-cabozantinib-for-patients-with-previously-treated" target="_blank" rel="noreferrer noopener">such as the lung and pancreas</a>.
The approval comes before the Prescription Drug User Fee Act action&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/01/b42896345/exelixis-provides-update-on-oncologic-drugs-advisory-committee-meeting-for-cabozantinib-cabometyx-" rel="noreferrer noopener">date of April 3</a>.
The FDA approval — adding to five previous approvals for Cabometyx — is based on the CABINET Phase 3 trial results.
Final progression-free survival results were&nbsp;<a target="_blank" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fir.exelixis.com%2Fnews-releases%2Fnews-release-details%2Fexelixis-announces-final-results-phase-3-pivotal-cabinet-study&amp;esheet=54210567&amp;newsitemid=20250219147539&amp;lan=en-US&amp;anchor=presented&amp;index=2&amp;md5=7b36ee82c7ce7195ef5a81ef129a2ad8" rel="noreferrer noopener">presented</a>&nbsp;at the 2024 European Society for Medical Oncology Congress and published in&nbsp;The New England Journal of Medicine.&nbsp;
In January 2025, the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for Neuroendocrine and Adrenal Tumors were updated to include cabozantinib as a category 1 preferred regimen for the majority of well-differentiated advanced NET following specific treatments and as a category 2A preferred regimen for other forms of advanced NET, depending on tumor grade and different requirements for prior therapy.
In February, Exelixis announced the final results from the phase 3 CheckMate-9ER pivotal trial evaluating Cabometyx (cabozantinib) in combination with Bristol-Myers Squibb Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Opdivo (nivolumab) versus sunitinib for patients with previously untreated advanced renal cell carcinoma (RCC).
After more than five years of follow-up, the findings demonstrated that the efficacy benefits of Cabometyx&nbsp;in combination with Opdivo were sustained long-term.
At a median follow-up of 67.6 months, Cabometyx, in combination with Opdivo, improved progression-free survival and overall survival compared with&nbsp;Pfizer Inc&#8217;s&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) Sutent (sunitinib) in the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43756537/exelixis-announces-final-five-year-follow-up-results-from-checkmate-9er-trial-evaluating-cabometyx" rel="noreferrer noopener">intent-to-treat population</a>.
EXEL Price Action: EXEL stock is down 2.31% at $36.83 at publication on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/03/44492174/palantir-partners-with-everfox-to-supercharge-us-military-tech" target="_blank" rel="noreferrer noopener">Everfox Partners With Palantir To Supercharge Military Tech: Details</a></li>
</ul>
Photo: Shutterstock

EXEL

FDA Approves Exelixis' Lead Cancer Drug Cabometyx For Expanded Use In Neuroendocrine Tumors

<a href="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C" title="https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C">https://www.nytimes.com/2025/03/26/health/usaid-cuts-gavi-bird-flu.html#:~:text=The%20Trump%20administration%20intends%20to,for%20efforts%20to%20combat%20malaria%2C</a>

Macro Economic Events

Global

Economics

NVAX

'The Trump Administration Intends To Terminate U.S. Financial Support For Gavi And To Significantly Scale Back Support For Efforts To Combat Malaria' - NY Times

ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc (GSK), with Pfizer Inc. and Shionogi as shareholders, is pleased to announce that APRETUDE (cabotegravir tablets and extended release injectable suspension) is now covered under the federal Non-Insured Health Benefits (NIHB) Program for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in at risk individuals who are HIV-1 negative.1
The Non-Insured Health Benefits (NIHB) Program provides eligible First Nations and Inuit people with coverage for a range of health benefits that are not otherwise covered through private, provincial, or territorial health insurance plans or social programs.2 In Canada approximately 10 per cent of all people living with HIV are Indigenous3, despite making up just five per cent of the country's population.4 Economic, social and systemic barriers, along with the lasting effects of racism and colonialism, all contribute to the disproportionate burden of HIV experienced by Indigenous people.5
The decision to reimburse APRETUDE through the NIHB Program will have a meaningful impact on HIV prevention efforts for eligible First Nations and Inuit people who are at-risk of HIV and could benefit from PrEP.

ViiV Healthcare Announces Reimbursement For APRETUDE For HIV-1 Pre-Exposure Prophylaxis Under The Non-Insured Health Benefits Program

On Sunday, Chinese Vice Premier He Lifeng met with top executives from Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Mastercard Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>), Eli Lilly and Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), Cargill, and other major firms.
What Happened: "China will continue to improve the business environment and welcome more investment by multinational companies in China, sharing opportunities for development," he told the leaders, describing the country's economy as "highly resilient" and "full of vitality."
Executives from medical device maker Medtronic PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) and investment management firm Conning were also in attendance, reported Reuters, citing a statement from China's Ministry of Commerce.
However, the statement did not specify where the meeting took place.
Many of the executives are in Beijing to attend the China Development Forum, where further high-level meetings, including a possible session with President Xi Jinping, are expected later this week, the report noted, citing unnamed sources.
See Also:&nbsp;<a href="https://www.benzinga.com/25/03/44272657/alibaba-chairperson-says-everyone-is-concerned-about-tariffs-as-he-expects-levies-on-chinese-evs" target="_blank" rel="noreferrer noopener">Alibaba's Joseph Tsai Says ‘Everyone Is Concerned About Tariffs,' As He Expects Levies On Chinese EVs</a>
Why It's Important: Beijing has ramped up efforts to attract foreign capital amid a slowing economy and fresh <a href="https://in.benzinga.com/news/global/25/03/44448798/china-ponders-export-limitations-to-quell-trumps-trade-onslaught">U.S. tariff headwinds</a> under President Donald Trump.
While American companies made up the largest group at this year's forum, sources say fewer U.S. CEOs attended compared to last year—signaling ongoing caution in cross-border corporate relations, the report noted.
Previously, the Chinese President expressed concerns about the possibility of China facing isolation similar to the Soviet Union during the Cold War. The ongoing trade war has heightened <a href="https://in.benzinga.com/25/03/44161587/is-china-apprehensive-of-losing-the-trade-war-to-the-us-china-could-get-isolated-like-moscow-fears-xi-jinping">fears of economic isolation</a>.
 Despite these challenges, <a href="https://in.benzinga.com/general/market-summary/25/03/44273552/ray-dalio-says-china-is-way-ahead-in-ai-and-robotics-us-lags-in-mass-production">China remains a leader</a> in technological advancements, particularly in artificial intelligence and robotics, according to investor Ray Dalio.
Image via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/25/02/44055314/mrbeast-lost-millions-on-amazons-beast-games-now-hes-looking-to-raise-hundreds-of-millions-to-take-h" target="_blank" rel="noreferrer noopener">MrBeast Lost Millions On Amazon's ‘Beast Games'—Now He's Looking To Raise Hundreds Of Millions To Take His Brand To The Next Level</a></li>
</ul>
Disclaimer:&nbsp;This content was partially produced with the help of&nbsp;<a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a>&nbsp;and was reviewed and published by Benzinga editors.

Markets

Tech

Media

China Courts Apple, Pfizer, Eli Lilly Amid US Pressure, Vice Premier Says Beijing 'Will Continue To Improve The Business Environment'

Companies with a long history of paying dividends and consistently hiking them remain appealing to income-focused investors. Pfizer, Spire, and TriCo Bancshares have rewarded shareholders for years and recently announced dividend increases. These companies currently offer dividend yields of around 3% to 6%.
Pfizer
Pfizer (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the U.S. and internationally.
Don't Miss:
<ul>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
<li>Hasbro, MGM Resorts, and Sketchers Use this Pre-IO AI Marketing Firm — <a href="https://www.benzinga.com/money/rad-intel">and You Can Own a Piece of it From $0.55/Share</a></li>
</ul>
Pfizer has raised its dividends every year for the last 15 years. In its most recent dividend hike announcement on Dec. 12, the company increased the quarterly payout from $0.42 to $0.43 per share, which is equal to an annual figure of $1.72 per share. The dividend yield on the stock currently stands at 6.60%.
Pfizer&#8217;s annual revenue as of Dec. 31 was $63.63 billion. In its Q4 2024 earnings report on Feb. 4, the company posted revenues of $17.76 billion and EPS of $0.63. Both figures came in above the consensus estimates.
If you invested $10,000 in Pfizer stock 10 years ago, how much would you have now? Check out this <a href="https://www.benzinga.com/markets/25/02/43431811/if-you-invested-10-000-in-pfizer-stock-10-years-ago-how-much-would-you-have-now">article by Benzinga</a> to learn more.
Trending: This Startup Is On The Brink Of A Huge Disruption To The $654 Billion Industry – <a href="https://www.benzinga.com/money/venhub-adv">Invest In It Before It Fulfills 800 Pre-Orders</a>
Spire
Spire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SR#NYSE">SR</a>) engages in the purchase, retail distribution, and sale of natural gas to residential, commercial, industrial, and other end-users of natural gas in the U.S.
The company has increased its dividends consecutively for the last 22 years. In its most recent dividend hike announcement on Nov. 14, Spire raised the quarterly payout from $0.755 to $0.785 per share, equal to an annual figure of $3.14 per share. Currently, the dividend yield on the stock is 4.12%.
Spire&#8217;s annual revenue as of Dec. 31 was $2.51 billion. According to the company's Q1 2025 earnings release on Feb. 5, it posted revenues of $669.10 million and EPS of $1.34. Both figures came in below the consensus estimates.
Check out this <a href="https://www.benzinga.com/insights/analyst-ratings/25/03/44139116/demystifying-spire-global-insights-from-4-analyst-reviews">article by Benzinga</a> for four analysts' insights on Spire.&nbsp;
See Also: This platform is reshaping how you invest in private companies —<a href="https://www.benzinga.com/money/kingscrowd-adv"> and you can be a part of it for $0.18 per share</a>
TriCo Bancshares
TriCo Bancshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBK#NASDAQ">TCBK</a>) operates as a bank holding company for Tri Counties Bank that provides commercial banking services to individual and corporate customers.
TriCo Bancshares has increased its dividends every year for the past 12 years. According to the company&#8217;s most recent dividend hike announcement on Feb. 22, 2024, its board raised the quarterly payout from $0.30 to $0.33 per share, equating to $1.32 annually. More recently, in its dividend announcement on Feb. 20, the company maintained the payout at the same level. The current yield on the dividend is 3.22%.
The company&#8217;s annual revenue as of Dec. 31 stood at $388.76 million. In its most recent earnings release on Jan. 23, the company posted Q4 2024 revenues of $100.36 million and EPS of $0.88. Both figures beat the Street estimates.&nbsp;
Pfizer, Spire, and TriCo Bancshares are good choices for investors seeking reliable passive income. Their dividend yields of around 3-6% and long history of consistent hikes make them attractive to income-focused investors.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>If there was a new fund backed by Jeff Bezos offering a <a href="https://www.benzinga.com/money/arrived-private-credit-fund">7-9% target yield with monthly dividends would you invest in it</a>?</li>
</ul>

TCBK

Looking For Yields: Pfizer, Spire, And TriCo Bancshares Are Consistent Moneymakers

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$24.00</td>
<td>$50.5K</td>
<td>2.0K</td>
<td>2.0K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$30.00</td>
<td>$60.2K</td>
<td>2.8K</td>
<td>1.6K</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/28/25</td>
<td>$320.00</td>
<td>$473.7K</td>
<td>609</td>
<td>602</td>
</tr>
<tr>
<td>HCA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$320.00</td>
<td>$312.3K</td>
<td>43</td>
<td>502</td>
</tr>
<tr>
<td>AKRO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$27.50</td>
<td>$35.0K</td>
<td>2.4K</td>
<td>469</td>
</tr>
<tr>
<td>GERN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$1.00</td>
<td>$33.7K</td>
<td>413</td>
<td>397</td>
</tr>
<tr>
<td>EWTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$30.00</td>
<td>$32.2K</td>
<td>5.4K</td>
<td>332</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$230.00</td>
<td>$53.6K</td>
<td>6.9K</td>
<td>295</td>
</tr>
<tr>
<td>CAH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$130.00</td>
<td>$44.2K</td>
<td>2.6K</td>
<td>188</td>
</tr>
<tr>
<td>BMY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$57.50</td>
<td>$64.9K</td>
<td>9.5K</td>
<td>167</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These itemized elaborations have been created using the accompanying table. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 56 day(s) on May 16, 2025. Parties traded 200 contract(s) at a $24.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $50.5K, with a price of $253.0 per contract. There were 2012 open contracts at this strike prior to today, and today 2073 contract(s) were bought and sold. 
• For VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we notice a put option trade that happens to be bearish, is expiring today. Parties traded 300 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $60.2K, with a price of $201.0 per contract. There were 2865 open contracts at this strike prior to today, and today 1625 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option sweep with bullish sentiment. It expires in 7 day(s) on March 28, 2025. Parties traded 600 contract(s) at a $320.00 strike. This particular put needed to be split into 57 different trades to become filled. The total cost received by the writing party (or parties) was $473.7K, with a price of $779.0 per contract. There were 609 open contracts at this strike prior to today, and today 602 contract(s) were bought and sold. 
• Regarding HCA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HCA#NYSE">HCA</a>), we observe a put option sweep with bearish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 474 contract(s) at a $320.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $312.3K, with a price of $660.0 per contract. There were 43 open contracts at this strike prior to today, and today 502 contract(s) were bought and sold. 
• For AKRO (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKRO#NASDAQ">AKRO</a>), we notice a call option trade that happens to be bearish, is expiring today. Parties traded 20 contract(s) at a $27.50 strike. The total cost received by the writing party (or parties) was $35.0K, with a price of $1750.0 per contract. There were 2499 open contracts at this strike prior to today, and today 469 contract(s) were bought and sold. 
• Regarding GERN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>), we observe a call option trade with bearish sentiment. It expires in 210 day(s) on October 17, 2025. Parties traded 397 contract(s) at a $1.00 strike. The total cost received by the writing party (or parties) was $33.7K, with a price of $85.0 per contract. There were 413 open contracts at this strike prior to today, and today 397 contract(s) were bought and sold. 
• Regarding EWTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EWTX#NASDAQ">EWTX</a>), we observe a call option sweep with bullish sentiment. It expires in 27 day(s) on April 17, 2025. Parties traded 104 contract(s) at a $30.00 strike. This particular call needed to be split into 21 different trades to become filled. The total cost received by the writing party (or parties) was $32.2K, with a price of $310.0 per contract. There were 5479 open contracts at this strike prior to today, and today 332 contract(s) were bought and sold. 
• For ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we notice a call option sweep that happens to be bearish, expiring in 91 day(s) on June 20, 2025. This event was a transfer of 198 contract(s) at a $230.00 strike. This particular call needed to be split into 35 different trades to become filled. The total cost received by the writing party (or parties) was $53.6K, with a price of $271.0 per contract. There were 6965 open contracts at this strike prior to today, and today 295 contract(s) were bought and sold. 
• For CAH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAH#NYSE">CAH</a>), we notice a call option sweep that happens to be bullish, is expiring today. Parties traded 137 contract(s) at a $130.00 strike. This particular call needed to be split into 14 different trades to become filled. The total cost received by the writing party (or parties) was $44.2K, with a price of $325.0 per contract. There were 2600 open contracts at this strike prior to today, and today 188 contract(s) were bought and sold. 
• Regarding BMY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), we observe a call option sweep with bearish sentiment. It expires in 91 day(s) on June 20, 2025. Parties traded 116 contract(s) at a $57.50 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $64.9K, with a price of $560.0 per contract. There were 9548 open contracts at this strike prior to today, and today 167 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

ABBV

AKRO

EWTX

GERN

VKTX

10 Health Care Stocks Whale Activity In Today's Session

The Association of the British Pharmaceutical Industry (ABPI) is urging ministers to address excessive levies on manufacturers to ensure the sector remains competitive globally.
The life sciences industry, a key pillar of the UK&#8217;s economic strategy, could struggle to attract investment unless payment rates are adjusted.
Last week, the government <a href="https://www.abpi.org.uk/media/news/2025/march/uk-set-to-demand-a-third-of-pharmaceutical-company-revenue-in-second-half-of-2025/" target="_blank" rel="noreferrer noopener">proposed</a> raising the Statutory Scheme payment rate for newer branded medicines from 15.5% to 32.2% of subject companies&#8217; National Health Service (NHS) sales in the second half of 2025.
The payment rate is the revenue companies must hand back to the government on their sales of branded medicines to the NHS. It is an additional charge to the taxes paid by companies.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44362710/uk-pharma-industry-trade-association-restores-wegovyozempic-maker-novo-nordisks-membership-after-two-years-of-suspension" rel="noreferrer noopener">UK Pharma Industry Trade Association Restores Wegovy/Ozempic Maker Novo Nordisk&#8217;s Membership After 2 Years Of Suspension</a>
UK pharmaceutical leaders from Amgen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), AstraZeneca Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Biogen Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>), Boehringer Ingelheim, Bristol Myers Squibb &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>), Daiichi Sankyo Ltd (OTC:<a class="ticker" href="https://www.benzinga.com/stock/DSNKY#OTC">DSNKY</a>), Gilead Sciences Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>), Merck &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Takeda Pharmaceutical Co Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) and UCB SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>) point to the challenges to investing in the U.K.
The pharmaceutical sector <a target="_blank" href="https://www.abpi.org.uk/media/news/2025/march/medicine-levy-makes-the-uk-un-investable-say-pharma-leaders/" rel="noreferrer noopener">contributes</a> over 17.6 billion pounds ($22.76 billion) directly to the U.K. economy, with an additional 45 billion generated through research and development spillovers.
However, companies argue that growth is being stifled due to escalating mandatory payments. Under the current system, firms must pay between 23.5% and 35.6% of their branded medicine sales revenue to the NHS. This is significantly higher than other European nations, where comparable rates range from 5.7% to 9%, ABPI writes.
The ABPI report highlights that while the UK once led in medicine availability, it has slipped to ninth place in Europe over the past decade. One year after launch, medicine usage in England is only 52% of the average of comparable nations, rising to 62% after five years.
Additionally, the UK has dropped from fourth to tenth in global rankings for phase 3 clinical trials, lagging behind Spain, Germany and Italy.
Investment in UK pharmaceutical research has also declined, with the country&#8217;s share of global R&amp;D investment falling from 7.3% to 5.7% in just three years.
This marks the fastest decline of any European G7 nation. Meanwhile, NHS funding has grown by 33% in real terms over the past decade, but spending on branded medicines has been capped at annual growth rates between 1.1% and 2%, declining by 11% when adjusted for inflation.
The industry and government have long collaborated on agreements to ensure NHS access to medicines.
The latest, the Voluntary Scheme for Branded Medicines, Pricing, Access, and Growth (VPAG), was intended to realign UK payment rates with international standards. While rates for newer medicines briefly dropped to 15.1% in 2024, they surged again in 2025 to 23.5% for newer medicines, with companies still paying 10.6%-35.6% for older products.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44436766/is-freeport-mcmorans-us-based-footprint-an-advantage-analyst-upgrades-stock-amid-copper-import-tariff-risk" target="_blank" rel="noreferrer noopener">Is Freeport-McMoRan&#8217;s US-Based Footprint An Advantage? Analyst Upgrades Stock Amid Copper Import Tariff Risk</a></li>
</ul>
Photo: Shutterstock

Eurozone

DSNKY

RHHBY

UCBJF

UCBJY

Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed

Press Releases

Quebec becomes first province to publicly reimburse APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP)

INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)

Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial

ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1

ViiV Healthcare's investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV

ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP

Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

Dexcom Appoints Jon Coleman as Chief Commercial Officer

ViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program

European Commission Approves Pfizer's RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease

ARVN

DXCM

MASI

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Haleon

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Takeda Pharmaceutical Co

Teva Pharmaceutical Industries Limited American Depositary Shares

Teva Pharmaceutical Indus

Verona Pharma plc - American Depositary Shares

Comments

Pfizer

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL